Prime Medicine Inc (PRME)

$4.10 -0.17 (-3.98%)
Market Cap 740.10M
Revenue (ttm) 2.98M
Net Income (ttm) -195.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,573.15%
Debt to Equity Ratio 0.00
Volume 2,180,100
Avg Vol 3,991,122
Day's Range N/A - N/A
Shares Out 180.51M
Stochastic %K 72%
Beta 2.69
Analysts Strong Sell
Price Target $6.46

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 465 0013
Address:
60 First Street, Cambridge, United States
SixAhoy
SixAhoy Dec. 13 at 5:48 AM
$PRME Discovered this company while reviewing Google’s Q3 2025 13F filings. Alphabet ($GOOGL) built a big position with 16,562,498 shares at est. avg price of $14.78.
0 · Reply
Dunkar
Dunkar Dec. 13 at 2:48 AM
$PRME glad to have a chunk of shares…looking forward to partnerships etc!
0 · Reply
SirSloth
SirSloth Dec. 13 at 2:42 AM
$PRME 🤷🏻‍♂️
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 12 at 11:04 PM
$PRME INTERESTING : https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says
0 · Reply
Elamenape2
Elamenape2 Dec. 12 at 9:07 PM
$PRME
0 · Reply
PorkchopSquats
PorkchopSquats Dec. 12 at 8:50 PM
$PRME Daily candles, what I am looking for on Monday. Will this shake off the bullshit or am I the one full of bullshit? Only time will tell.
2 · Reply
APman
APman Dec. 12 at 4:47 PM
$PRME A gamble
3 · Reply
Markus01
Markus01 Dec. 12 at 4:12 PM
$PRME Prime Medicine - Volume Shelf Launch Price Target: $5.17 Price is moving off the volume shelf in the last week, moving higher. Momentum looks to be increasing. Target is set at $5.17 at previous resistance.
0 · Reply
jschor88
jschor88 Dec. 12 at 3:41 PM
$PRME $ALT starter position in PRME. Let’s see that 600% 💪
1 · Reply
Benpsf
Benpsf Dec. 12 at 3:04 PM
$PRME Prime Medicine - Volume Shelf Launch Price Target: $5.17 Price is moving off the volume shelf in the last week, moving higher. Momentum looks to be increasing. Target is set at $5.17 at previous resistance.
0 · Reply
Latest News on PRME
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Dec 7, 2025, 8:05 AM EST - 6 days ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 18 days ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 12, 2025, 2:51 PM EST - 4 weeks ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 4 weeks ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 10:21 AM EST - 5 weeks ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 5 weeks ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Nov 3, 2025, 8:01 AM EST - 5 weeks ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 30, 2025, 4:01 PM EDT - 6 weeks ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Prime Medicine to Participate in Upcoming Investor Conferences

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 5:38 PM EDT - 3 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 3 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

PRME Revenue Misses by 73%

Aug 7, 2025, 12:27 PM EDT - 4 months ago

PRME Revenue Misses by 73%

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Aug 1, 2025, 4:01 PM EDT - 4 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 9:33 PM EDT - 4 months ago

Prime Medicine Announces Pricing of Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 30, 2025, 4:01 PM EDT - 4 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 8:10 AM EDT - 5 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 16, 2025, 7:00 AM EDT - 5 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Jul 7, 2025, 4:45 PM EDT - 5 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:31 AM EDT - 7 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 19, 2025, 8:30 AM EDT - 7 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 7 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Why Prime Medicine Stock Was Climbing Higher This Week

Mar 20, 2025, 6:48 PM EDT - 9 months ago

Why Prime Medicine Stock Was Climbing Higher This Week

Why Prime Medicine Stock Is Soaring Today

Mar 19, 2025, 2:56 PM EDT - 9 months ago

Why Prime Medicine Stock Is Soaring Today

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Mar 18, 2025, 7:00 AM EDT - 9 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 28, 2025, 8:00 AM EST - 10 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 10 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Jan 30, 2025, 12:26 PM EST - 11 months ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

12 High-Growth Stocks That Could Deliver Parabolic Returns

Oct 28, 2024, 10:00 AM EDT - 1 year ago

12 High-Growth Stocks That Could Deliver Parabolic Returns

ACHR APLD CRSP JOBY LUNR NTLA NVTS

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Why I Keep Buying These 14 Incredible Growth Stocks

Oct 16, 2024, 9:45 AM EDT - 1 year ago

Why I Keep Buying These 14 Incredible Growth Stocks

ACHR ASPN CRSP GE HWM JOBY KTOS

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Sep 30, 2024, 6:08 PM EDT - 1 year ago

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Prime Medicine Unveils Strategically Focused Pipeline

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

2 Growth Stocks That Could Make You Richer

Aug 28, 2024, 8:15 AM EDT - 1 year ago

2 Growth Stocks That Could Make You Richer

RKLB

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

May 25, 2024, 4:10 AM EDT - 1 year ago

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

GTLB

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

2 Magnificent Growth Stocks With Room to Run

Mar 27, 2024, 8:45 AM EDT - 1 year ago

2 Magnificent Growth Stocks With Room to Run

TLRY

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 20, 2024, 4:01 PM EST - 1 year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

SixAhoy
SixAhoy Dec. 13 at 5:48 AM
$PRME Discovered this company while reviewing Google’s Q3 2025 13F filings. Alphabet ($GOOGL) built a big position with 16,562,498 shares at est. avg price of $14.78.
0 · Reply
Dunkar
Dunkar Dec. 13 at 2:48 AM
$PRME glad to have a chunk of shares…looking forward to partnerships etc!
0 · Reply
SirSloth
SirSloth Dec. 13 at 2:42 AM
$PRME 🤷🏻‍♂️
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 12 at 11:04 PM
$PRME INTERESTING : https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says
0 · Reply
Elamenape2
Elamenape2 Dec. 12 at 9:07 PM
$PRME
0 · Reply
PorkchopSquats
PorkchopSquats Dec. 12 at 8:50 PM
$PRME Daily candles, what I am looking for on Monday. Will this shake off the bullshit or am I the one full of bullshit? Only time will tell.
2 · Reply
APman
APman Dec. 12 at 4:47 PM
$PRME A gamble
3 · Reply
Markus01
Markus01 Dec. 12 at 4:12 PM
$PRME Prime Medicine - Volume Shelf Launch Price Target: $5.17 Price is moving off the volume shelf in the last week, moving higher. Momentum looks to be increasing. Target is set at $5.17 at previous resistance.
0 · Reply
jschor88
jschor88 Dec. 12 at 3:41 PM
$PRME $ALT starter position in PRME. Let’s see that 600% 💪
1 · Reply
Benpsf
Benpsf Dec. 12 at 3:04 PM
$PRME Prime Medicine - Volume Shelf Launch Price Target: $5.17 Price is moving off the volume shelf in the last week, moving higher. Momentum looks to be increasing. Target is set at $5.17 at previous resistance.
0 · Reply
PorkchopSquats
PorkchopSquats Dec. 12 at 2:43 PM
$PRME Last time it got stuck breaking out at this level, it took five days of grinding before lift off on day six. Today is day five. Don’t know if this will pull the same move, but curious to see if a pattern develops.
2 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Dec. 12 at 2:22 PM
$PRME Daily Deion
0 · Reply
dbagging
dbagging Dec. 12 at 1:40 AM
$PRME one more
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Dec. 12 at 1:29 AM
$PRME Okay last one
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Dec. 12 at 1:12 AM
$PRME 😳
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 11 at 9:53 PM
$CABA $RXRX $PRME $RLYB
0 · Reply
JoeBio
JoeBio Dec. 11 at 9:30 PM
$PRME Sold for the one day gain of $13,900....tomorrow's another wonderful opportunity be it here or elsewhere in the all too often manipulated market especially small cap biotechs....May all your trades and investments be profitable!
1 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Dec. 11 at 8:58 PM
$PRME Mcnulty indicator is fraudulent!
1 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Dec. 11 at 8:01 PM
$PRME 2500 followers
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 11 at 7:19 PM
$ABCL $ABCL , $CABA , $PRME, $NTLA, $RXRX ALL POISED TO HAVE A BANNER 2026
1 · Reply
Reanimated666
Reanimated666 Dec. 11 at 4:59 PM
$PRME I just gotta do me baby if that’s buying or selling
0 · Reply
Stonkerzzz
Stonkerzzz Dec. 11 at 4:27 PM
$PRME bipolar today
1 · Reply